CPH.TO Stock - Cipher Pharmaceuticals Inc.
Unlock GoAI Insights for CPH.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $33.36M | $21.16M | $20.68M | $21.94M | $21.61M |
| Gross Profit | $24.10M | $17.09M | $16.68M | $18.26M | $18.55M |
| Gross Margin | 72.2% | 80.8% | 80.7% | 83.2% | 85.9% |
| Operating Income | $7.85M | $11.53M | $12.04M | $11.82M | $12.20M |
| Net Income | $11.54M | $20.38M | $26.64M | $7.76M | $4.55M |
| Net Margin | 34.6% | 96.3% | 128.8% | 35.4% | 21.1% |
| EPS | $0.47 | $0.80 | $1.06 | $0.29 | $0.17 |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
Visit WebsiteEarnings History & Surprises
CPH.TOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 6, 2025 | $0.29 | $0.30 | +1.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.21 | $0.30 | +41.1% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.11 | $0.10 | -9.1% | ✗ MISS |
Q1 2025 | Mar 18, 2025 | $0.21 | $0.13 | -38.1% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.14 | $0.01 | -92.9% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.12 | $0.12 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $0.10 | $0.20 | +100.0% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $0.10 | $0.30 | +200.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $0.07 | $0.27 | +285.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $0.09 | $0.12 | +33.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $0.08 | $0.10 | +25.0% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $0.09 | $0.77 | +755.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $0.09 | $0.10 | +11.1% | ✓ BEAT |
Q3 2022 | Jul 21, 2022 | $0.13 | $0.11 | -17.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $0.11 | $0.10 | -9.2% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $0.11 | $0.11 | 0.0% | = MET |
Q4 2021 | Nov 11, 2021 | $0.09 | $0.05 | -44.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $0.08 | $0.10 | +25.0% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.09 | $0.05 | +155.6% | ✓ BEAT |
Q1 2021 | Mar 18, 2021 | $0.07 | $-0.00 | -106.8% | ✗ MISS |
Latest News
Frequently Asked Questions about CPH.TO
What is CPH.TO's current stock price?
What is the analyst price target for CPH.TO?
What sector is Cipher Pharmaceuticals Inc. in?
What is CPH.TO's market cap?
Does CPH.TO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CPH.TO for comparison